title: Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.
abstract: BACKGROUND
  Pancreatic cancer is the fourth leading cause of cancer death in the United States. Surgery offers the only chance for cure. However, less than twenty percent of patients are considered operative candidates at the time of diagnosis. A common reason for being classified as unresectable is advanced loco-regional disease.A review of the literature indicates that almost nine hundred patients with pancreatic cancer have received regional chemotherapy in the last 15 years. Phase I studies have shown regional administration of chemotherapy to be safe. The average reported response rate was approximately 26%. The average 1-year survival was 39%, with an average median survival of 9 months. Of the patients that experienced a radiographic response to therapy, 78 (78/277, 28%) patients underwent exploratory surgery following regional chemotherapy administration; thirty-two (41%) of those patients were amenable to pancreatectomy. None of the studies performed analyses to identify factors predicting response to regional chemotherapy.Progressive surgical techniques combined with current neoadjuvant chemoradiotherapy strategies have already yielded emerging support for a multimodality approach to treatment of advanced pancreatic cancer.Intravenous gemcitabine is the current standard treatment of pancreatic cancer. However, >90% of the drug is secreted unchanged affecting toxicity but not the cancer per se. Gemcitabine is converted inside the cell into its active drug form in a rate limiting reaction. We hypothesize that neoadjuvant regional chemotherapy with continuous infusion of gemcitabine will be well tolerated and may improve resectability rates in cases of locally advanced pancreatic cancer.
  
  
  METHODS
  This is a phase I study designed to evaluate the feasibility and toxicity of super-selective intra-arterial administration of gemcitabine in patients with locally advanced, unresectable pancreatic adenocarcinoma. Patients considered unresectable due to locally advanced pancreatic cancer will receive super-selective arterial infusion of gemcitabine over 24 hours via subcutaneous indwelling port. Three to six patients will be enrolled per dose cohort, with seven cohorts, plus an additional six patients at the maximum tolerated dose; accrual is expected to last 36 months. Secondary objectives will include the determination of progression free and overall survival, as well as the conversion rate from unresectable to potentially resectable pancreatic cancer.
  
  
  BACKGROUND
  ClinicalTrials.gov ID: NCT01294358.
authors: Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors: Jeremy L
authors: JL
authors: Davis
authors: Prakash
authors: P
authors: Pandalai
authors: R Taylor
authors: RT
authors: Ripley
authors: Russell C
authors: RC
authors: Langan
authors: Seth M
authors: SM
authors: Steinberg
authors: Melissa
authors: M
authors: Walker
authors: Mary Ann
authors: MA
authors: Toomey
authors: Elliot
authors: E
authors: Levy
authors: Itzhak
authors: I
authors: Avital
references: Ann Surg Oncol. 2006 Aug;13(8):1035-46
references: 16865597
references: J Clin Oncol. 2006 Sep 1;24(25):4196-201
references: 16943537
references: J Clin Oncol. 2003 Sep 15;21(18):3402-8
references: 12885837
references: J Clin Oncol. 2001 Feb 15;19(4):1001-7
references: 11181662
references: Jpn J Clin Oncol. 2008 Apr;38(4):268-74
references: 18375446
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: J Am Coll Surg. 1999 Jul;189(1):1-7
references: 10401733
references: Ann Surg. 1958 Oct;148(4):616-32
references: 13583933
references: J Clin Oncol. 2009 Aug 10;27(23):3778-85
references: 19581537
references: J Urol. 2010 Jan;183(1):56-61
references: 19913833
references: J Clin Oncol. 1991 Mar;9(3):491-8
references: 1999720
references: J Natl Compr Canc Netw. 2007 Nov;5(10):998-1033
references: 18053426
references: Br J Cancer. 1996 Aug;74(3):460-2
references: 8695365
references: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002093
references: 16855985
references: J Clin Oncol. 2007 May 20;25(15):1960-6
references: 17452677
references: Cancer Invest. 2005;23(2):145-54
references: 15813508
references: J Clin Oncol. 1984 May;2(5):498-504
references: 6547166
references: Med Oncol. 2006;23(3):369-76
references: 17018894
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Ann Surg Oncol. 1999 Sep;6(6):582-90
references: 10493628
references: Cancer. 2000 Jul 15;89(2):303-13
references: 10918160
references: JAMA. 2007 Jan 17;297(3):267-77
references: 17227978
references: J Hepatol. 2001 Sep;35(3):421-30
references: 11592607